0
points
1
94%
0
points
1
94%
The Revised International Prognostic Index (R-IPI) is a modification of the original IPI specifically developed to improve prognostic stratification of diffuse large B-cell lymphoma (DLBCL) patients treated in the rituximab era. Published by Sehn and colleagues in 2007 in Blood, the R-IPI demonstrated that the same five IPI factors could be regrouped to provide better discrimination when rituximab-containing chemotherapy is used.
The addition of rituximab to CHOP chemotherapy represented the most significant advance in DLBCL treatment in decades, improving overall survival by approximately 10-15% across all risk groups. This improvement had the effect of shifting the distribution of outcomes, making the original four-tier IPI risk grouping less discriminative. The R-IPI addressed this by consolidating patients into three risk groups with better separation of survival curves.
The R-IPI uses the same five factors as the original IPI (age >60, elevated LDH, ECOG >=2, stage III-IV, >=2 extranodal sites) but redistributes them into three groups: very good prognosis (0 factors, ~94% 4-year OS), good prognosis (1-2 factors, ~79% 4-year OS), and poor prognosis (3-5 factors, ~55% 4-year OS). This redistribution was derived from analysis of 365 patients treated with R-CHOP.
A key finding of the R-IPI study was that patients with zero IPI factors represent a distinct very-good-prognosis group with outcomes approaching cure in the vast majority of cases. The original IPI grouped these patients with those having 1 factor, diluting the prognostic information. The R-IPI separation of zero-factor patients provides more accurate counseling and treatment planning.
Another important observation was that no R-IPI group had a 4-year OS below approximately 50%, compared to the original IPI where the high-risk group had substantially worse outcomes. This reflects the overall improvement in DLBCL outcomes with rituximab-based therapy. However, the poor-prognosis R-IPI group still has significant room for improvement and remains a focus of clinical trial development.
The R-IPI has been validated in multiple independent cohorts and is commonly reported alongside the original IPI and NCCN-IPI in clinical studies. Its advantage is its simplicity and the clear identification of the very-good-prognosis group. Its limitation is the broad middle group (1-2 factors) that encompasses considerable heterogeneity in outcomes.
The R-IPI uses the same 5 IPI factors (1 point each) but regroups into three risk categories:
R-IPI Risk Groups:
Risk Group: 1=Very Good (0), 2=Good (1-2), 3=Poor (3-5).
Score 0 (Very Good, Group 1): Excellent prognosis with ~94% 4-year OS. Standard R-CHOP is highly effective. Score 1-2 (Good, Group 2): Favorable prognosis with ~79% 4-year OS. Standard therapy is appropriate. Score 3-5 (Poor, Group 3): Approximately 55% 4-year OS. Consider intensified therapy, clinical trial enrollment, or novel treatment approaches for this group.
Inputs
Results
No adverse IPI factors. R-IPI very good prognosis. 94% 4-year OS. Standard R-CHOP is highly curative.
Inputs
Results
Three adverse factors. R-IPI poor prognosis. 55% 4-year OS. Consider intensified approaches.
The Revised International Prognostic Index is a modification of the original IPI that regroups the same five risk factors into three categories (very good, good, poor) that better discriminate outcomes in patients treated with rituximab-containing chemotherapy.
R-IPI uses the same five factors but groups them as: 0 factors=very good, 1-2=good, 3-5=poor. Standard IPI uses: 0-1=low, 2=low-intermediate, 3=high-intermediate, 4-5=high.
The addition of rituximab to chemotherapy improved outcomes across all IPI groups, reducing the discriminative ability of the original four-tier IPI. R-IPI provides better separation of survival curves in the rituximab era.
Very good (0 factors): ~94%. Good (1-2 factors): ~79%. Poor (3-5 factors): ~55%. These are population-level estimates from the rituximab era.
Both are valid. NCCN-IPI provides more granular age and LDH scoring and better identifies the highest-risk patients. R-IPI is simpler and better identifies the very-good-prognosis zero-factor group.
Patients in the very good prognosis group (score 0) have approximately 94% long-term survival, with most cured by standard R-CHOP. However, no prognostic score can guarantee individual outcomes.
R-IPI was developed and validated specifically for DLBCL. Other lymphoma subtypes have their own prognostic systems. Using R-IPI for follicular or mantle cell lymphoma is not appropriate.
Rituximab is a monoclonal antibody targeting CD20 on B lymphocytes. Its addition to CHOP chemotherapy (R-CHOP) was proven to improve survival in DLBCL in the landmark GELA trial published in 2002.
Standard R-CHOP remains first-line. Novel approaches being studied include polatuzumab-R-CHP, dose-adjusted EPOCH-R, CAR-T cell therapy consolidation, and bispecific antibodies for high-risk patients.
No, R-IPI is based on clinical factors only. Incorporating molecular subtypes (GCB vs ABC by gene expression profiling) and genetic features (MYC/BCL2 double-hit) can further refine prognosis beyond R-IPI.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!
NCCN-IPI (Lymphoma)
Oncology Risk & Prognosis Calculators
IPI24 (Lymphoma)
Oncology Risk & Prognosis Calculators
IPSS-R (Myelodysplastic Syndrome)
Oncology Risk & Prognosis Calculators
WPSS (WHO Prognostic Scoring System)
Oncology Risk & Prognosis Calculators
ISS (International Staging System for Myeloma)
Oncology Risk & Prognosis Calculators
R-ISS (Revised ISS for Myeloma)
Oncology Risk & Prognosis Calculators
